Home › MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
 

Keywords :   


MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

2015-05-07 18:57:31| Biotech - Topix.net

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that it has been notified by NINDS that the ongoing clinical trial of MN-166 in progressive multiple sclerosis is now fully enrolled. Enrollment activities at all 28 sites are now closed and no new patients will be accepted into the study.A Randomization is expected to be completed in approximately 4 - 6 weeks.

Tags: full ms trial phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05China hits back at US and EU as trade rows deepen
20.05How should countries deal with falling birth rates?
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Water investors have withdrawn billions, says research
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
More »